Literature DB >> 6228192

In vitro activity of ciprofloxacin (Bay o 9867).

R J Fass.   

Abstract

The in vitro activities of ciprofloxacin (Bay o 9867) and seven comparative antimicrobial agents against 664 aerobic and facultatively anaerobic bacterial isolates were studied. Minimal inhibitory concentrations (MICs) of ciprofloxacin were less than or equal to 2 micrograms/ml for Enterobacteriaceae, less than or equal to 8 micrograms/ml for nonfermentative gram-negative bacilli, less than or equal to 4 micrograms/ml for gram-positive cocci, less than or equal to 0.03 micrograms/ml for Aeromonas hydrophila and Pasteurella multocida, and less than or equal to 1 microgram/ml for Listeria monocytogenes. MICs for multi-drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa were less than or equal to 4 micrograms/ml. Ciprofloxacin MICs were consistently 0 to 4 (usually 2 to 3) dilution steps lower than those of a related drug, norfloxacin (P less than 0.0001). For most species, they were lower than MICs of cefotaxime, aztreonam, theinamycin, mezlocillin, trimethoprim-sulfamethoxazole, and amikacin. With all eight drugs, increasing the inoculum size by 100-fold had a variable effect on MICs which was species related. Ciprofloxacin is a potent broad-spectrum new antimicrobial agent.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6228192      PMCID: PMC185375          DOI: 10.1128/AAC.24.4.568

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  2 in total

1.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

2.  In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim.

Authors:  H C Neu; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

  2 in total
  75 in total

1.  In vitro activity of Bay 12-8039, a new 8-methoxyquinolone.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Ciprofloxacin concentration in the rabbit aqueous humor and vitreous following intravenous and subconjunctival administration.

Authors:  W Behrens-Baumann; J Martell
Journal:  Infection       Date:  1988       Impact factor: 3.553

3.  Spontaneous quinolone resistance in Serratia marcescens due to a mutation in gyrA.

Authors:  B L Masecar; N J Robillard
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

4.  Steady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa.

Authors:  D Fabre; F Bressolle; R Gomeni; C Arich; F Lemesle; H Beziau; M Galtier
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

5.  Comparative study of ciprofloxacin versus co-trimoxazole in the treatment of Salmonella enteric fever.

Authors:  B M Limson; R T Littaua
Journal:  Infection       Date:  1989 Mar-Apr       Impact factor: 3.553

6.  The Inoculum Effect in the Era of Multidrug Resistance: Minor Differences in Inoculum Have Dramatic Effect on MIC Determination.

Authors:  Kenneth P Smith; James E Kirby
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

7.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

8.  Susceptibility of multiply antibiotic-resistant pneumococci to the new quinoline antibiotics, nalidixic acid, coumermycin, and novobiocin.

Authors:  M E Gombert; T M Aulicino
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

9.  Comparative activities of ciprofloxacin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia.

Authors:  J B Schiff; G J Small; J E Pennington
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

Review 10.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.